Fei Ma

10.0k total citations · 2 hit papers
448 papers, 6.0k citations indexed

About

Fei Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Fei Ma has authored 448 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 261 papers in Oncology, 157 papers in Pulmonary and Respiratory Medicine and 143 papers in Cancer Research. Recurrent topics in Fei Ma's work include HER2/EGFR in Cancer Research (97 papers), Cancer Treatment and Pharmacology (85 papers) and Breast Cancer Treatment Studies (79 papers). Fei Ma is often cited by papers focused on HER2/EGFR in Cancer Research (97 papers), Cancer Treatment and Pharmacology (85 papers) and Breast Cancer Treatment Studies (79 papers). Fei Ma collaborates with scholars based in China, United States and United Kingdom. Fei Ma's co-authors include Binghe Xu, Ying Fan, Pin Zhang, Haili Qian, Binghe Xu, Yang Luo, Ruigang Cai, Jiayu Wang, Zongbi Yi and Qiao Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Journal of Biological Chemistry.

In The Last Decade

Fei Ma

415 papers receiving 5.9k citations

Hit Papers

Single-cell analyses reveal key immune cell subsets assoc... 2021 2026 2022 2024 2021 2025 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
    2021 434 citations Hongnan Mo, Xiaoying Sun et al. profile →
  2. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
    2025 25 citations Hongnan Mo, Xiaoying Sun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Ma China 35 3.1k 2.0k 1.8k 1.6k 608 448 6.0k
Lisa G. Horvath Australia 46 2.2k 0.7× 2.4k 1.2× 1.6k 0.9× 2.5k 1.6× 525 0.9× 198 6.0k
Alfredo Budillon Italy 50 2.6k 0.8× 3.7k 1.9× 1.1k 0.6× 974 0.6× 471 0.8× 203 6.7k
Jiuwei Cui China 44 2.6k 0.8× 3.1k 1.6× 1.8k 1.0× 1.4k 0.9× 591 1.0× 361 7.4k
Elizabeth Claire Dees United States 34 4.5k 1.5× 3.0k 1.5× 2.9k 1.6× 1.4k 0.9× 395 0.6× 127 7.9k
Marcus Schmidt Germany 42 5.0k 1.6× 2.4k 1.2× 2.7k 1.5× 2.8k 1.8× 785 1.3× 297 9.0k
Marius Ilié France 42 3.3k 1.1× 1.8k 0.9× 2.4k 1.3× 2.3k 1.5× 317 0.5× 165 5.9k
Mario Scartozzi Italy 44 3.7k 1.2× 1.7k 0.8× 1.5k 0.8× 2.1k 1.3× 378 0.6× 343 6.4k
Ludovic Lacroix France 47 2.7k 0.9× 2.7k 1.4× 2.0k 1.1× 2.3k 1.5× 451 0.7× 220 7.5k
Gérard Zalcman France 39 3.5k 1.1× 2.1k 1.1× 890 0.5× 3.0k 2.0× 476 0.8× 299 6.7k
Lisa Rydén Sweden 44 2.7k 0.9× 2.1k 1.1× 2.8k 1.5× 1.1k 0.7× 373 0.6× 187 5.7k

Countries citing papers authored by Fei Ma

Since Specialization
Citations

This map shows the geographic impact of Fei Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Ma more than expected).

Fields of papers citing papers by Fei Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Ma. The network helps show where Fei Ma may publish in the future.

Co-authorship network of co-authors of Fei Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Ma. A scholar is included among the top collaborators of Fei Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Ma. Fei Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lan, Bo, Jiayu Wang, Qiao Li, et al.. (2025). The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. The Breast. 81. 104470–104470. 3 indexed citations
2.
Ma, Fei, Jingfen Wang, Herui Yao, et al.. (2024). Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1110–1110. 2 indexed citations
3.
Liu, Shuning, et al.. (2024). Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial.. Journal of Clinical Oncology. 42(16_suppl). e13015–e13015.
4.
Zhang, Di, Lixi Li, & Fei Ma. (2024). Integrative analyses identified gap junction beta‐2 as a prognostic biomarker and therapeutic target for breast cancer. PubMed. 3(4). e128–e128. 1 indexed citations
5.
Mo, Hongnan, Yongpei Yu, Xiaoying Sun, et al.. (2024). Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature Medicine. 30(9). 2528–2539. 11 indexed citations
6.
7.
Sun, Yuxin, Xiaoxuan Li, Shouhua Wang, et al.. (2023). Drug resistance and new therapies in gallbladder cancer. Drug Discoveries & Therapeutics. 17(4). 220–229. 6 indexed citations
8.
Dai, Huaping, Fei Ma, Yanhong Ren, Shanshan Chen, & Yiqun Li. (2023). Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Current Medical Science. 43(1). 1–12. 7 indexed citations
9.
10.
Li, Lixi, Di Zhang, & Fei Ma. (2022). Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma. Technology in Cancer Research & Treatment. 21. 2213859293–2213859293. 1 indexed citations
11.
Lv, Dan, Bo Lan, Li Zhang, et al.. (2022). Association between depression and anxiety status of breast cancer patients before adjuvant chemotherapy and chemotherapy‐induced adverse events. Cancer Medicine. 12(4). 4794–4800. 8 indexed citations
12.
Yi, Zongbi, Fei Ma, Guohua Rong, et al.. (2020). Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. Cancer Communications. 40(6). 260–269. 17 indexed citations
13.
Guo, Jianbin, et al.. (2020). The characteristics of isolated para-aortic lymph node metastases in endometrial cancer and their prognostic significance. Therapeutic Advances in Medical Oncology. 12. 3863548076–3863548076. 10 indexed citations
14.
Li, Qiao, Xiuwen Guan, Shanshan Chen, et al.. (2019). Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research. 25(17). 5212–5220. 61 indexed citations
15.
Guo, Jianbin, et al.. (2019). The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?. Archives of Gynecology and Obstetrics. 300(5). 1399–1404. 6 indexed citations
16.
17.
Ma, Fei, et al.. (2018). [The status quo and analysis of quality control of cancer chemotherapy in 76 hospitals in Beijing].. PubMed. 40(4). 280–283. 1 indexed citations
18.
Cai, Wangyu, Gang Chen, Qicong Luo, et al.. (2017). PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells. Molecular Cancer Therapeutics. 16(6). 1187–1198. 37 indexed citations
19.
Ye, Kaixiong, Jian Lü, Fei Ma, Alon Keinan, & Zhenglong Gu. (2014). Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. Proceedings of the National Academy of Sciences. 111(29). 10654–10659. 192 indexed citations
20.
Zhang, Pin, Bailin Zhang, Xiang Wang, et al.. (2012). [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].. PubMed. 34(10). 770–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa G. Horvath Breakdown of academic impact, for papers by Alfredo Budillon Breakdown of academic impact, for papers by Jiuwei Cui Breakdown of academic impact, for papers by Elizabeth Claire Dees Breakdown of academic impact, for papers by Marcus Schmidt Breakdown of academic impact, for papers by Marius Ilié Breakdown of academic impact, for papers by Mario Scartozzi Breakdown of academic impact, for papers by Ludovic Lacroix Breakdown of academic impact, for papers by Gérard Zalcman Breakdown of academic impact, for papers by Lisa Rydén
Rankless by CCL
2026